An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

Inclusion criteria

• Healthy as determined by a responsible and experienced physician
• Male or female between 18 and 60 years of age inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of:

• Non-childbearing potential defined
• Child-bearing potential and agrees to use one of the contraception methods listed
• Male subjects must agree to use one of the contraception methods listed
• Body weight > 50 kg and body mass index (BMI) within the range of 18 - 30kg/m2 (inclusive).
• Normal or High Normal blood pressure
• 24hr holter with no clinically significant findings.
• QTcB or QTcF < 450 msec at screening and pre-dose.
• Creatinine Clearance within the normal range at screening and pre-dose.
• Liver function test within normal limits at screening and pre-dose.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

• Subjects who are vegetarian or vegan, or for any other reason be unwilling to consume a high fat meal.
• The subject has either a previous disease or current medical condition
• Has made a suicide attempt in the past or, in the investigator's judgment, poses significant suicide risk.
• Presence of clinically significant proteinuria or hematuria or other clinically significant findings in urinalysis.
• Subjects with symptoms of urinary dysfunction.
• Subjects whose ECG shows PR interval is >220 msec, or presence of intraventricular conduction disturbances (complete or incomplete BBB), at screening or prior to dosing.
• Presence of clinically significant arrhythmias.
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• Current or chronic liver disease or biliary abnormalities. Medical history positive for biliary signs and symptoms (cholecystectomy is acceptable).
• History of regular alcohol consumption within 6 months of the study.
• A positive drug/alcohol screen at screening and / or pre-dose.
• A positive test for HIV antibody.
• The subjects smokes more than 10 cigarettes per week.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Use of prescription or non-prescription drugs.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
• Lactating females.
• Unwillingness or inability to follow the procedures outlined in the protocol.
• Subject is mentally or legally incapacitated.